Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared with Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; GSK 2321138A
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
Most Recent Events
- 09 Jan 2024 Status changed from recruiting to discontinued as per sponsor decision, but without any safety concerns.
- 09 Jan 2024 This trial has been discontinued in Poland, According to European Clinical Trials Database record.
- 05 Jan 2024 This trial has been discontinued in Czech Republic.